China In Vitro Diagnostics Market Analysis by Mordor Intelligence
The China in vitro diagnostics (IVD) market stands at USD 18.65 billion in 2025 and is forecast to reach USD 23.81 billion by 2030, registering a 5.01% CAGR. Demand is buoyed by a rapidly ageing population, the country’s high chronic‐disease burden, and steady policy support for primary-care diagnostics. Streamlined National Medical Products Administration (NMPA) pathways shorten review timelines for high-value tests, while volume-based procurement (VBP) anchors price transparency and encourages wider adoption in lower-tier settings. Local manufacturers leverage 20% procurement price advantages to capture share, and artificial-intelligence (AI) tools embedded in tier-2/3 hospitals slash turnaround times from 30 minutes to five. Concurrently, disposable platforms gain traction as infection-control protocols persist and point-of-care (POC) solutions penetrate rural clinics.
Key Report Takeaways
- By test type, molecular diagnostics led with 39.37% of the China in vitro diagnostics (IVD) market share in 2024; immunodiagnostics is projected to expand at a 5.84% CAGR to 2030.
- By product, reagents and consumables accounted for 62.29% of the China in vitro diagnostics (IVD) market size in 2024, while software and services record the fastest CAGR at 6.35% through 2030.
- By usability, reusable devices dominated with 72.41% share in 2024; disposable devices grow quickest at a 6.26% CAGR to 2030.
- By application, infectious-disease testing captured 42.5% share, whereas oncology diagnostics advance at a 6.12% CAGR between 2025-2030.
- By end user, hospitals and clinics held 52.6% revenue share in 2024, while independent clinical laboratories post the highest growth at 6.07% CAGR.
China In Vitro Diagnostics Market Trends and Insights
Drivers Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
High burden of chronic & infectious diseases | +1.2% | National; tier-1 cities concentrated | Long term (≥ 4 years) |
Ageing population accelerating diagnostic demand | +1.0% | National; higher in eastern provinces | Long term (≥ 4 years) |
Government price-volume procurement expanding access | +0.8% | National; early roll-out in major cities | Medium term (2-4 years) |
Rapid decentralisation to point-of-care settings | +0.7% | Tier-2/3 cities & rural areas | Medium term (2-4 years) |
AI-assisted test-menu optimisation in tier-2/3 hospitals | +0.5% | Tier-2/3 cities | Short term (≤ 2 years) |
Source: Mordor Intelligence
High Burden of Chronic & Infectious Diseases
Diabetes affects over 140 million adults, prompting sustained demand for glucose monitoring and HbA1c testing. HIV cases reached nearly 1.3 million by 2023, broadening screening beyond traditional risk groups. C-reactive protein testing shows 72.23% sensitivity for tuberculosis screening among HIV-infected persons, highlighting the need for multi-marker panels[1]China CDC Weekly Editorial Board, “Evolution of HIV Epidemic and Emerging Challenges — China, 1989–2023,” China CDC Weekly, weekly.chinacdc.cn. Point-of-care HbA1c tests deliver cost-utility ratios of USD 500.06/QALY in cities and USD 185.10/QALY in rural areas, well within national willingness-to-pay thresholds. These factors collectively sustain molecular and immunoassay volumes, particularly in decentralised settings.
Ageing Population Accelerating Diagnostic Demand
China counts 310 million citizens aged 60 and above, intensifying utilisation of cardiovascular, oncology and cognitive assays. Coordination studies point to widening gaps between elderly demand and diagnostic capacity in secondary cities. Government spending is projected to hit CNY 205 trillion (USD 28.2 trillion) by 2030, with diagnostics earmarked for geriatric care. Health All-in-One Machines boosted patient visits 37.85% and clinic revenue 54.03% in Hainan’s rural network. The demographic shift therefore underpins automated, multi-condition test platforms.
Government Price-Volume Procurement (PVP) Expanding Access
The first insulin tender cut median prices 42.08% and saved USD 2.85 billion in year one. Diagnostic VBP now applies identical mechanisms, granting domestic devices a 20% price edge and triggering uptake in under-served areas. Although reimbursement delays persist, the 2024 National Medical Insurance Drug List, effective January 2025, establishes predictable coding for new assays, widening the payer base.
Rapid Decentralisation to Point-of-Care Settings
Portable systems such as iPonatic deliver 30-minute infectious-disease panels from fingertip samples[2]Jun-Feng Li, “Streamlined POCT Solution for Rapid Infectious-Disease Detection,” Nature Scientific Reports, nature.com. Emergency departments adopting “point-of-careology” report materially shorter therapeutic turnaround times. Rural pilots covering 2,700 village clinics showcase scalable pathways for nationwide deployment. Connectivity and cloud dashboards enable remote supervision, plugging urban–rural gaps.
Restraints Impact Analysis
Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Uncertain reimbursement for novel assays | -0.6% | National; tier-2/3 cities affected more | Medium term (2-4 years) |
Stringent NMPA clinical-trial requirements | -0.4% | National | Medium term (2-4 years) |
Data-privacy compliance costs (PIPL, CSL) | -0.3% | National; multinationals hit harder | Short term (≤ 2 years) |
Source: Mordor Intelligence
Uncertain Reimbursement for Novel Assays
Volume-based procurement favours established technologies, delaying payment codes for emerging molecular and AI-enabled tests[3]National Healthcare Security Administration, “2023 Healthcare Security Statistical Bulletin,” NHSA, nhsa.gov.cn. Diagnosis-Intervention Packet pilots in 71 cities underscore reimbursement evolution but also risk inequities across insurance schemes, slowing novel assay uptake.
Stringent NMPA Clinical-Trial Requirements
Revised Class II/III guidelines demand extensive real-world validation, stretching registration by up to nine months and costing USD 28,850 for Class II filings. Mandatory human-factors testing with Chinese users adds hurdles for foreign devices.
Segment Analysis
By Test Type: Molecular Diagnostics Leads Market Evolution
Molecular diagnostics held 39.37% share in 2024, anchoring the China in vitro diagnostics (IVD) market. Immunodiagnostics rises fastest at 5.84% CAGR to 2030, backed by automation and infection-surveillance requirements. BGI Genomics’ legal success against Illumina and a 4% uptick in sequencing-device sales illustrate home-grown momentum. Clinical chemistry remains relevant through entrenched hospital networks, while rapid nucleic-acid methods and CRISPR detection bolster pandemic preparedness.
The China in vitro diagnostics (IVD) industry benefits from AI-enhanced test-menu optimisation in secondary hospitals, improving throughput. Microbiology enjoys renewed focus after COVID-19, with C-reactive protein tests expanding tuberculosis programmes. Urinalysis and niche panels gain share through integrated POC devices that lower handling errors. Advances in microfluidics and sample-to-answer cartridges keep molecular diagnostics at the innovation frontier.
Note: Segment shares of all individual segments available upon report purchase
By Product: Software Integration Drives Digital Transformation
Reagents and consumables generated 62.29% revenue in 2024 and remain the backbone of recurring income for the China in vitro diagnostics (IVD) market. Yet software and services post a 6.35% CAGR to 2030 as laboratories digitise. Mindray’s purchases of HyTest and DiaSys reinforce vertical integration, while Chemclin’s automated immunodetection systems marry local cost advantages with export-level quality.
Laboratory-information management systems, AI analytics and cloud dashboards transform workflows, and blockchain tools address data-security mandates under the Personal Information Protection Law. Instrument makers pivot to subscription models bundling hardware, software and consumables, cushioning VBP price pressure. The China in vitro diagnostics (IVD) industry thereby transitions from product-centric to platform-centric value creation.
By Usability: Disposable Devices Gain Momentum
Reusable analyzers represented 72.41% of the 2024 market, but disposable cartridges clock a 6.26% CAGR on infection-control and POC trends. iPonatic’s single-use cartridges cost USD 0.50 and consolidate sample extraction and detection, opening complex testing to rural clinics. BGI’s Bloomics micro-needle collection system exemplifies patient-friendly disposables.
Pandemic protocols entrenched single-use habits, and environmental considerations now spur biodegradable substrates and recycling schemes. Reusable systems remain vital in high-throughput urban labs, yet hybrid models emerge, pairing capital equipment with disposable microfluidic chips to balance cost-per-test with biosafety.
By Application: Oncology Diagnostics Accelerate Growth
Infectious-disease testing captured 42.5% share in 2024, underscoring continued surveillance priorities. Oncology lines produce the fastest 6.12% CAGR as China expands lung-, colorectal- and liver-cancer screening. Guardant Health’s liquid-biopsy licence with Adicon signals global-local collaboration.
Diabetes, cardiology and autoimmune panels maintain steady growth as chronic‐disease programmes widen. Biosensors targeting miRNAs and exosomes advance gastrointestinal-tumour detection. These developments fortify the China in vitro diagnostics (IVD) market’s pivot to precision medicine.
Note: Segment shares of all individual segments available upon report purchase
By End User: Independent Labs Drive Market Expansion
Hospitals and clinics owned 52.6% share in 2024, anchored by integrated care pathways. Independent laboratories record a 6.07% CAGR, propelled by mutual-recognition policies that cut redundant tests and by specialised molecular workflows beyond hospital scope. AI roll-outs in smart wards, such as at Shandong University Second Hospital, illustrate the broader digital transition in provider settings.
Academic institutes fuel assay validation and nurture start-ups, sustaining a virtuous cycle of research and commercialisation. Tele-consult platforms link remote clinics with central labs, reinforcing decentralisation and expanding the addressable base of the China in vitro diagnostics (IVD) market.
Geography Analysis
Eastern provinces, Guangdong, Zhejiang and Shanghai, anchor R&D and manufacturing clusters for the China in vitro diagnostics (IVD) market, hosting leaders such as Mindray and BGI Genomics. Beijing functions as regulatory nexus, where NMPA reforms streamline approvals and attract early-stage ventures. Tier-2/3 cities experience accelerated infrastructure investments, illustrated by Health All-in-One Machine deployments across 2,700 Hainan village clinics that boost local diagnostics utilisation.
Volume-based procurement evens access across provinces, standardising pricing and rewarding scale efficiencies. Western regions rely on telehealth and POC tools to overcome geographic isolation, while the Yangtze River Delta’s supply-chain depth enables both domestic consumption and exports. Roche’s facility in Shanghai’s Zhangjiang High-tech Park shows continued foreign commitment to local production.
Cross-border Greater Bay Area frameworks allow technology transfer among Guangdong, Hong Kong and Macau under strict data-sovereignty rules. AI adoption maps closely to regional GDP, with tier-1 hubs piloting diagnostic large-language models, while inland provinces prioritise foundational lab capacity. This heterogeneous landscape ultimately reinforces a unified but locally adapted China in vitro diagnostics (IVD) market.
Competitive Landscape
The market is moderately consolidated: top domestic and international players together hold majority of the revenue, with the remainder dispersed among regional specialists. Mindray pursues vertical integration through HyTest and DiaSys acquisitions, while investing in APT Medical to extend into interventional therapeutics.
International incumbents like Roche face VBP-driven price compression yet retain premium niches via advanced analyzers and companion diagnostics. Emerging disruptors—Chemclin, Wondfo and microfluidic CDMO Colace—scale rapidly on domestic procurement preference, AI analytics and export ambitions.
Strategic themes centre on AI, cloud-managed platforms and POC miniaturisation. Companies differentiate through total-solution bundles that combine reagents, instruments and analytics within compliance envelopes governed by the Personal Information Protection Law and Cybersecurity Law. The ensuing competitive intensity propels continuous innovation while aligning with national self-reliance goals.
China In Vitro Diagnostics Industry Leaders
-
F Hoffmann-la Roche Ltd
-
Thermo Fisher Scientific Inc
-
Abbott Laboratories
-
Shenzhen Mindray Bio-Medical Electronics Co. Ltd
-
Danaher Corp.
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- January 2025: BGI Genomics and WeGene form a consumer-grade genetic-testing alliance leveraging Bloomics micro-needle collection and DNA-methylation clocks.
- January 2025: Boditech Med, a player in point-of-care diagnostics, signed a Memorandum of Understanding (MOU) with Autobio Diagnostics Co., Ltd., a in vitro diagnostics (IVD) company based in China. This partnership seeks to drive the development and expansion of key product sales.
China In Vitro Diagnostics Market Report Scope
As per the scope of this report, in vitro diagnostics involves medical devices and consumables that are utilized to perform in vitro tests on various biological samples. They are used to diagnose various medical conditions, such as chronic diseases. The China in vitro diagnostics market is segmented by test type, product, usability, application and end-user. By test type, the market is segmented into clinical chemistry, molecular diagnostics, immunodiagnostics, hematology, and other types. By product, the market is segmented into instruments, reagents, and other products. By usability, the market is segmented into disposable IVD devices and reusable IVD devices. By application, the market is segmented into infectious disease, diabetes, cancer/oncology, cardiology, autoimmune disease, nephrology, and other applications. By end user, the market is segmented into diagnostic laboratories, hospitals, and clinics, and other end users. For each segment, the market size is provided in terms of USD value.
By Test Type | Clinical Chemistry |
Molecular Diagnostics | |
Immunodiagnostics | |
Hematology | |
Coagulation | |
Microbiology | |
Urinalysis | |
Others | |
By Product | Instruments |
Reagents & Consumables | |
Software & Services | |
By Usability | Disposable IVD Devices |
Re-usable IVD Devices | |
By Application | Infectious Disease |
Diabetes | |
Oncology | |
Cardiology | |
Auto-immune Disorders | |
Nephrology | |
Pregnancy & Women's Health | |
Others | |
By End-user | Independent Clinical Laboratories |
Hospitals & Clinics | |
Academic / Research Institutes |
Clinical Chemistry |
Molecular Diagnostics |
Immunodiagnostics |
Hematology |
Coagulation |
Microbiology |
Urinalysis |
Others |
Instruments |
Reagents & Consumables |
Software & Services |
Disposable IVD Devices |
Re-usable IVD Devices |
Infectious Disease |
Diabetes |
Oncology |
Cardiology |
Auto-immune Disorders |
Nephrology |
Pregnancy & Women's Health |
Others |
Independent Clinical Laboratories |
Hospitals & Clinics |
Academic / Research Institutes |
Key Questions Answered in the Report
What is the current size of the China in vitro diagnostics (IVD) market?
It is valued at USD 18.65 billion in 2025, with a forecast to reach USD 23.81 billion by 2030.
Which segment holds the largest share by test type?
Molecular diagnostics leads with 39.37% market share in 2024.
Why are disposable diagnostic devices growing quickly?
Post-pandemic infection-control protocols and wider point-of-care deployment propel a 6.26% CAGR for disposable devices through 2030.
How does volume-based procurement influence pricing?
Initial tenders cut median prices by around 42% and expand access, favouring companies that can deliver scale efficiencies.
What role does AI play in China’s diagnostics landscape?
AI platforms in tier-2/3 hospitals reduce diagnosis times from 30 minutes to five and support error detection, improving overall laboratory efficiency.
Which application is expanding fastest?
Oncology diagnostics posts the highest growth at a 6.12% CAGR, reflecting expanded national cancer-screening protocols.
Page last updated on: June 13, 2025